The life sciences & health care (LSHC) sector enters 2026 in a mode of regulatory acceleration. AI is no longer on the horizon: it is embedded across the entire medical product lifecycles, impacting discovery to commercialization. Drug and device sponsors are equipped with critical new advantages, including faster approval pathways, modern technology, and real-world data utilization. “Most Favored Nation” proposals are reshaping the global pricing reference dynamic. M&A, licensing, and commercial transaction frameworks are being rewritten as supply chains are tested. Energy concerns are growing as AI tools test consumption constraints, and EU regulators scrutinize environmental green claims.
Our annual LSHC Horizons Guide, which discusses these issues and other rapidly evolving legal and regulatory paradigms, is now online here.
LSHC manufacturing strategies in 2026 are being transformed by factors including energy constraints, AI tools, inspections concerns, and geopolitical factors that encourage domestic production. At the international level, tariff regimes and trade restrictions such as BIOSECURE have taken center stage. U.S. onshoring and friendshoring strategies must now pivot as FDA has advanced QMSR harmonization with international standards. For pharmaceuticals and biotechnology companies, DSCSA interoperability ripples downstream to dispensers, requiring upstream partners to shore up contracts. In the EU, the Critical Medicines Act, ESMP, and Pharma Package are tightening supply chain shortage prevention and reporting, with CS3D pushing due diligence policy proposals into practice.
New joint guidance on artificial intelligence from the FDA and EMA herald a more harmonized, risk‑based regulatory outlook. In the U.S., FDA is expanding AI use for reviews and surveillance, as the government increasingly scrutinizes AI‑based chatbots, CDS tools, and ambient scribes, particularly where consumer‑facing claims or mental health‑related use cases surface.
In the EU, a pivotal simplification could exempt most AI-enabled devices from the AI Act and relocate obligations back into the MDR/IVDR. The UK continues to position itself as a pragmatic technology testbed, as demonstrated by its AI Airlock program. Latin America is also focused on digital health modernization—as evidenced by Mexico's landmark 2026 digital health amendment—as well as on regulatory convergence, and promotion of treatments for areas of unmet medical need, including oncology drugs, vaccines, and biosimilars.
Our clients are forging ahead in new frontiers for advanced therapies and biologics. FDA increasingly promotes flexibility for rare disease treatments, as well as cell, tissue, and gene therapies, as evidenced by the “plausible mechanism” route, and voucher pilots. Biosimilars are trending toward analytics‑first evidence and interchangeability without switching studies, narrowing the gap between designations and accelerating market formation. In the EU, we see hospital exemptions competing with approved ATMPs, and sponsors planning for data collection, pharmacovigilance, and cross‑border restrictions that are embedded in the refreshed EU framework. As a critical part of regenerative medicine development, hospitals are now globalizing as integrated enterprises—exporting advisory and clinical services, telemedicine, and data collaborations—thereby exponentiating regulatory touchpoints.
In the data privacy & cybersecurity domain, Europe's regulatory agenda is shifting from conceptual to operational: the EU Data Act imposes device and wearable data access and data‑license constraints on non‑personal product data; the Digital Omnibus proposal fortifies trade secret protections; and the EHDS ushers in broad secondary‑use pathways, elevating many private actors to “health data holders.” Meanwhile, cookie consent and tracking enforcement are hardening in the EU and the UK, as FDA also elevates ML‑specific cybersecurity expectations for device submissions. Federated learning, albeit privacy-preserving, still mandates threat modeling, bias controls, and transfer‑risk assessments.
In the compliance space, AI litigation strategy is evolving with adaptive models, where version control, audit logs, and explainability become increasingly vital evidentiary assets. The EU product liability directive and national implementations are widening liability, including recall‑based presumptions of defect. Algorithmic pricing litigation has reached health care adjacencies, and competition watchdogs are raising scrutiny of patent lifecycle and disparagement conduct. The U.S. is ramping up drug advertisement enforcement programs, and investigations are also on the rise across Latin America, where social media and digital promotion oversight in particular is sharpening. Meanwhile, the French government is strengthening measures to curb drug spending by restricting fast-track reimbursements while imposing stricter price controls.
Anti‑corruption trends and False Claims Act litigation have added new diligence priorities, with both deal and dispute playbooks evolving to price divergence into milestones, and to ring‑fence assets for regulatory exposure. Significant enforcement momentum alongside growing judicial uncertainty has intensified compliance risks in the U.S., particularly for Anti-Kickback Statute violations and cyber fraud. Before the Unified Patent Court, life sciences jurisprudence evolves on imminent infringement, long‑arm jurisdiction via regulatory roles, and inventive step analyses. Arbitration toolkits are expanding in 2026 to contain multi‑party risk. In the global antitrust space, below‑threshold merger scrutiny and FDI/FSR considerations now routinely craft sequencing and conditions.
Aiming to speed clinical trials, the proposed EU Biotech Act would compress study timelines and harmonize documentation requirements. In addition, many EU Member States and the UK are adding national fast track pathways. For its part, FDA is promoting decentralized clinical trial (DCT) elements, while also revamping inspection expectations, and embracing Bayesian methods that foster adaptive designs, dose-finding studies, and confirmatory trials, including those relying on external data borrowing. Real-world evidence has moved from rhetoric to accepted inputs when data fitness is demonstrated.
Across the Asia Pacific (APAC) region, multi‑country trials increasingly depend on DCTs. The LSHC landscape moves at uneven but accelerating speed as major markets adopt ambitious and novel AI regulatory frameworks. Japan, India, Singapore, and South Korea are widening their digital health sandboxes to promote AI‑enabled devices and regenerative medicines. China maintains some of the world's most detailed rules on generative AI and digital health data governance, while constricting regulations governing cross‑border transfer of genetic, clinical, and biometric data.
Due in part to its mandate of local investor participation, dealmaking structures in China increasingly focus on balancing control with staged risk, such as license‑to‑acquire and NewCo vehicles. Doing business in APAC requires bespoke transactional, regulatory, and data strategies for each market, paired with collaboration architectures that can withstand divergence in approval timelines. Companies must navigate a region where opportunity is high but regulatory fragmentation is profound.
In 2026, the rapid pace of technological development alongside global political uncertainty demands integrated regulatory navigation. The bar for compliance has been raised as AI and data regimes mature, supply resiliency become legally testable, pricing experiments globalize, and courts recalibrate liability to software‑defined products. LSHC companies that succeed won't merely comply: they'll operationalize regulation as strategy—using it to accelerate product quality, derisk transactions, and earn durable market access.
Read about these issues and more in our Life Sciences & Health Care Horizons Guide for 2026.
[View source.]
